Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about using distilled water as a solvent for topical finasteride to reduce systemic absorption. The user is considering avoiding ethanol and propylene glycol to achieve this.

The conversation expresses frustration over the lack of clear evidence regarding the effectiveness and systemic impact of topical Dutasteride for hair loss treatment, despite years of discussion. People are criticized for not conducting proper research and for providing contradictory anecdotal claims.

A user is considering switching from oral to topical finasteride to reduce systemic DHT impact and is exploring ethossomal finasteride for better skin penetration and potential hair regrowth. They found ethossomal finasteride in Brazil and are seeking opinions on its effectiveness compared to other topical delivery methods.

Topical finasteride reduces scalp DHT, with some going systemic. Using 0.025% at 1ml per day can stabilize hair loss without side effects.

Applying minoxidil immediately after microneedling at 0.5mm can cause stinging and potential systemic absorption, so some users prefer to wait 12-24 hours. Others report no issues with immediate application, but caution is advised to avoid irritation and side effects.

PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.

Topical finasteride (P-3074) can inhibit scalp DHT by up to 70%, with some users experiencing systemic absorption similar to oral use. Users discuss varying application frequencies and concentrations, with some noticing side effects when overused.

Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

Topical finasteride can effectively reduce scalp DHT by targeting local enzymes, despite less systemic impact compared to oral forms. Combining oral dutasteride with topical finasteride and minoxidil may enhance hair loss prevention, though evidence of its effectiveness is limited.

The user transitioned from finasteride to RU58841 and oral minoxidil to maintain hair gains while avoiding systemic DHT suppression. They have not experienced increased shedding or side effects since stopping finasteride and hope RU58841 will preserve their hair.

The conversation discusses the need for a localized 5-alpha reductase inhibitor that only affects the scalp without systemic side effects, similar to pyrilutamide's approach. Current treatments like topical liposomal finasteride and dutasteride are mentioned, but concerns about their systemic effects and lack of research are highlighted.

GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.

Using both oral and topical minoxidil is likely safe, but be cautious of increased systemic absorption. The best tretinoin dosage to enhance minoxidil effectiveness is not specified.

Topical finasteride results in plasma levels 100 times lower than oral finasteride, potentially reducing systemic side effects. Users report similar efficacy with fewer side effects, suggesting a preference for topical application.

The conversation discusses concerns about oral minoxidil potentially aging the face by affecting collagen, questioning its systemic effects. The user has successfully used topical minoxidil for years and is hesitant to switch to oral minoxidil.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

The conversation discusses using a low dose of topical finasteride to achieve hair benefits with minimal systemic exposure. Users share experiences and opinions on dosing, systemic buildup, and side effects of both topical and oral finasteride.

The conversation is about the appropriate wait time to apply topical finasteride after microneedling to prevent it from going systemic. The user is combining finasteride with minoxidil and is unsure whether to wait 24 or 48 hours after microneedling before applying the treatment.

Fluridil is hard to obtain and only available in Slovakia and Czechia, with no systemic side effects but possibly limited effectiveness compared to finasteride. The original poster is using finasteride and minoxidil without success and is considering trying fluridil despite its cost.

Using topical finasteride with creatine might help reduce hair loss by targeting local DHT while maintaining normal systemic levels, but results are uncertain without testing. Users report mixed experiences with topical treatments like finasteride, dutasteride, RU58841, and minoxidil, with some seeing regrowth and others experiencing side effects.

Topical spironolactone is discussed as a hair loss treatment, with concerns about its effectiveness and side effects compared to finasteride and minoxidil. Users mention its unpleasant smell, potential systemic absorption, and suggest alternatives like pyrilutamide and alfatradiol.

A 20-year-old is experiencing hair thinning and is considering Clascoterone and Minoxidil as treatments, avoiding finasteride due to concerns about fertility and hormones. A suggestion was made to use Clascoterone for local DHT targeting and combine it with Minoxidil for maintenance and regrowth while avoiding systemic side effects.

Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.

PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.

The conversation is about finding a safe carrier for topical antiandrogens like finasteride, kx-826, RU58841, and dutasteride to minimize systemic absorption and side effects. The user experiences side effects from these treatments and is seeking advice on carriers that reduce these effects.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

The conversation discusses using a 0.03% topical Dutasteride solution for hair loss, as it may be more effective than Finasteride with fewer systemic side effects. OP plans to apply it daily for 100 days, then reduce frequency, due to past negative cognitive effects from oral treatments.

A 23-year-old is experiencing hair loss and is considering whether to try oral minoxidil due to fear of side effects, after inconsistent use of topical minoxidil. They are advised to try topical minoxidil consistently first, as it has fewer systemic effects.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

The conversation is about a user considering reducing their dutasteride dose due to side effects like lower libido and watery semen. They plan to use dutasteride mesotherapy every three months to maintain hair while reducing systemic DHT suppression.